These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 7339482)
41. Itraconazole-A New Player in the Therapy of Advanced Basal Cell Carcinoma: A Case Report. Ciążyńska M; Narbutt J; Skibińska M; Lesiak A JCO Oncol Pract; 2020 Dec; 16(12):837-838. PubMed ID: 32813585 [No Abstract] [Full Text] [Related]
42. The therapeutic potential of lymphokines in neoplastic disease. Pulley MS; Dumonde DC Ann N Y Acad Sci; 1988; 521():274-89. PubMed ID: 3288044 [No Abstract] [Full Text] [Related]
43. Lymphokine: prospect as a cancer agent. Reynolds RD; Khoiasteh A; Papermaster BW; McEntire J; Garcia A; Kapoor A; Kapoor N; Doyle MK; Walter J; Anson NO Mo Med; 1984 Sep; 81(9):604-6. PubMed ID: 6482864 [No Abstract] [Full Text] [Related]
44. Mechanics of intralesional injection. Abd-el-Aziz AM; el-Gawhari AI; Mohey-el-Din SM J Egypt Med Assoc; 1970; 53(9):718-20. PubMed ID: 5524178 [No Abstract] [Full Text] [Related]
45. Preliminary observations on tumor regressions induced by local administration of a lymphoid cell culture supernatant fraction in patients with cutaneous metastatic lesions. Papermaster BW; Holtermann OA; Klein E; Djerassi I; Rosner D; Dao T; Costanzi JJ Clin Immunol Immunopathol; 1976 Jan; 5(1):31-47. PubMed ID: 1261098 [No Abstract] [Full Text] [Related]
46. Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Gyurova MS; Stancheva MZ; Arnaudova MN; Yankova RK Dermatol Online J; 2006 Mar; 12(3):25. PubMed ID: 16638439 [TBL] [Abstract][Full Text] [Related]
47. New intralesional therapy for basal cell carcinoma by 2% zinc sulphate solution. Sharquie KE; Al-Nuaimy AA; Al-Shimary FA Saudi Med J; 2005 Feb; 26(2):359-61. PubMed ID: 15770334 [No Abstract] [Full Text] [Related]
48. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). Kurtis B; Rosen T J Dermatol Surg Oncol; 1980 Feb; 6(2):122-7. PubMed ID: 7354186 [TBL] [Abstract][Full Text] [Related]
49. Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. Fink-Puches R; Wolf P; Kerl H Arch Dermatol; 1997 Dec; 133(12):1494-5. PubMed ID: 9420532 [No Abstract] [Full Text] [Related]
50. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Itkin A; Gilchrest BA Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801 [TBL] [Abstract][Full Text] [Related]
51. Advances in the treatment of basal cell carcinoma: the promise of pharmacologic therapy. Vander Straten M; Lee P; Weitzul S; Cockerell CJ; Tyring SK Adv Dermatol; 2000; 16():299-318; discussion 319. PubMed ID: 11094632 [No Abstract] [Full Text] [Related]
52. Basal cell carcinomas: treatment with intralesional injection of lymphokine fraction. Rodes ND; McEntire JE; Lopez M; Perez-Mesa C; Gay C; Decker M; Kaltenbach ML; Papermaster BW Mo Med; 1981 Dec; 78(12):735-6, 739. PubMed ID: 7339482 [No Abstract] [Full Text] [Related]